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Abstract: A vast amount of data on nanomedicines is being generated and published, and natural 
language processing (NLP) approaches can automate the extraction of unstructured text-based 
data. Annotated corpora are a key resource for NLP and information extraction methods which 
employ machine learning. Although corpora are available for pharmaceuticals, resources for 
nanomedicines and nanotechnology are still limited. To foster nanotechnology text mining 
(NanoNLP) efforts, we have constructed a corpus of annotated drug product inserts taken from 
the US Food and Drug Administration’s Drugs@FDA online database. In this work, we present 
the development of the Engineered Nanomedicine Database corpus to support the evaluation 
of nanomedicine entity extraction. The data were manually annotated for 21 entity mentions 
consisting of nanomedicine physicochemical characterization, exposure, and biologic response 
information of 41 Food and Drug Administration-approved nanomedicines. We evaluate the 
reliability of the manual annotations and demonstrate the use of the corpus by evaluating two 
state-of-the-art named entity extraction systems, OpenNLP and Stanford NER. The annotated 
corpus is available open source and, based on these results, guidelines and suggestions for future 
development of additional nanomedicine corpora are provided.
Keywords: nanotechnology, informatics, natural language processing, text mining, corpora
Introduction
Nanotechnology is enabling new strategies to detect and treat disease through 
multifunctional (eg, targeted, activatable, diagnostic, and therapeutic) drug design. 
Formulating a drug as a nanomedicine can also improve its therapeutic index by chang-
ing its stability, pharmacokinetics, and toxicity. For several decades, researchers have 
primarily designed new nanomedicines based on an empirical approach. However, the 
number of possible nanomedicine formulations continues to increase exponentially 
as new nanomaterials, surface coatings, bioconjugates, and drug combinations are 
developed. As a consequence, experimentally assessing all possible nanomedicine 
formulations for efficacy and safety is not feasible or realistic. There is a critical need 
to automatically extract information and synthesize knowledge and trends in nano-
medicine research to rationally prioritize testing and development.
Natural Language Processing (NLP) approaches can semi-automate the process of 
converting text-based unstructured data (eg, full-text articles) to structured data (eg, 
tables). Interest in applying NLP techniques to nanotechnology has increased over the 
years, with a number of systems developed for nanomedicine information extraction 
and nanotechnology patent mining.1 Most NLP algorithms rely on annotated corpora for 
both training and evaluation of the system. Despite development of several NanoNLP 
systems, only one nanotechnology-related corpus has been described in the literature.2 
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Motivated by the need for a nanomedicine corpus, we present 
the Engineered Nanomedicine Database (END).
The main objective of this paper is to propose a frame-
work for creating an annotated corpus for nanomedicine 
entity extraction. Toward this objective, we validate a manu-
ally annotated corpus of US Food and Drug Administration 
(FDA)-approved nanomedicines from drug product inserts 
collected from the Drugs@FDA Database.3 The extracted 
entities consist of nanoparticle physicochemical properties, 
exposure parameters, and biologic response information for 
41 drugs. We evaluate the precision, recall, and F-measure 
between expert and non-expert generated annotations and 
evaluate the performance of two state-of-the-art named entity 
extraction systems applied to the corpus. To promote future 
development of nanomedicine corpora and entity extraction 
systems, we provide the expert annotated corpus as open 
source (http://rampages.us/nanoinformatics/resources).
The remainder of this paper is as follows. First, we 
describe related work associated with entity extraction. 
Second, we describe our method in developing the END 
dataset. Third, statistical analysis of the annotation process 
and the contents of the completed END corpus are presented. 
Finally, use of the corpus for creation of a named entity rec-




The documents selected for annotation were drug product 
labels for 41 nanomedicines that are currently approved 
for clinical use by the FDA. The labels were obtained from 
the Drugs@FDA online database. This document type was 
chosen for two reasons: compared to nanomedicines in the 
pipeline, FDA-approved nanomedicines are 1) expected 
to have the most number of unique publications in the 
literature; 2) already being prescribed by physicians, and 
therefore, mentions could be contained in clinical notes. 
The list of nanomedicines chosen was based on review 
articles.4,5 The annotated drug product labels described 
nanomedicines consisting of liposomes, micelles, polymer 
conjugates, protein conjugates, and nanoparticles, which are 
listed in Table 1. The extracted entities relate to nanoparticle 
physicochemical properties, exposure, pharmacokinetics, 
and biologic response in addition to description information. 
A complete list of these entities is shown in Table 2.
annotation process
To develop an entity extractor, a training set composed 
of relevant texts that have been manually annotated by 
domain experts is required. Manually annotated corpora 
are traditionally prepared by the NLP community through 
collective shared tasks. When conducted by individuals, it 
has be reported to take more than 10 hours to annotate a 
single research paper.2 Recruiting professional nanomedicine 
researchers to donate this time is challenging; therefore, we 
hypothesized that a potential solution could be to train non-
expert (student) annotators. It has been suggested that, with 
training, annotation tasks can be crowdsourced to non-experts 
to build annotated corpora of biomedical literature.6,7 In this 
work, we assessed the quality of annotations generated by 
non-experts to those of a domain expert on texts describing 
nanomedicines. The annotators included three undergradu-
ate research assistants and one professor from the Virginia 
Commonwealth University Department of Chemical and Life 
Science and Engineering. The research assistants were enter-
ing their junior year and were given training in annotation as 
outlined in the following section. The General Architecture 
for Text Engineering (GATE)8 open source, annotation, 
Table 1 Us FDa-approved nanomedicines from the year 1975 to 2013
Platform Drug
conjugate
antibody–drug adcetris®, Bexxar®, Kadcyla®, Zevalin®
Polymer–aptamer Macugen®
Polymer–protein adagen®, cimzia®, Krystexxa®, Mircera®, Neulasta®, Oncaspar®, Pegasys®, Peg-Intron®, somavert®
Protein–drug abraxane®, Ontak®
lipid
liposome abelcet®, amBisome®, amphotec®, DaunoXome®, Depocyt®, DepoDur®, Diprivan®, Doxil®, Marquibo®, Visudyne®
Micelle estrasorb™, Taxotere®
Nanocrystal emend®, Megace es®, rapamune®, Tricor®, Triglide®
Nanoparticle
Iron Feraheme®, Ferrlecit®, Venofer® 
elestrin®
Polymer copaxone®, eligard®, renagel®, Welchol®
Abbreviation: FDa, Us Food and Drug administration.





and development environment for computational language 
processing was used to manually annotate the drug product 
labels. An example of annotation is presented in Figure 1. The 
entity annotation guidelines, which include entity definitions 
and annotation rules (Table 3), were developed to reduce 
potential interpretation differences between annotators.
annotator training
The following procedure was employed when training the 
students:
•	 “Preannotation guideline discussion phase:” In this phase, 
orthography and grammar rules, multiword entity rules, 
and definitions of entities were discussed. All students 
completed this phase.
•	 “Pilot annotation phase:” In this phase, the annotators 
were trained on six entities (active ingredient, dose, 
indication, nanoparticle, route of administration, trade 
name). Their annotations were compared with the 
expert’s annotations, and all differences were discussed 
with them. All students completed this phase.
•	 “Annotation phase:” In this phase, all 21 entities were 
given to the annotators. Orthography and grammar rules, 
multiword entity rules, and definitions of entities were 
again discussed. The annotators were also informed that 
if they had any questions, they were to ask the expert 
annotator. All questions and responses were circulated 
among all three of the annotators. One student fully com-
pleted and two students partially completed this phase.
Results
characteristics of corpus
Table 4 shows a high-level breakdown of the expert-annotated 
drug label inserts within the END corpus. Within the 41 drug 
label inserts, there are 28,276 sentences and 465,890 words 
and a total of 22,033 annotations. On average, each drug 
label contains 690 (SD 496) sentences, 11,363 (SD 5,897) 
words, and 537 (SD 310) annotations. The largest class of 
nanomedicines, liposomes, was also examined to determine 
if restricting to a subset could be representative of the corpus 
overall. Table 5 shows the number of annotated mentions, 
the number of unique mentions, and the number of labels 
containing mentions for each entity. Not all labels contained 
a mention for all 21 entity types. The number of mentions 
across the drug labels varied from 6,689 (adverse reaction) 
to 7 (particle diameter). The unique types of mentions also 
varied, with the largest number annotated for adverse reaction 
where 1,773 of the 6,689 mentions were unique.
evaluation of non-expert annotations
We evaluated the annotation agreement using precision, 
recall, and F-measure, which were calculated using the GATE 
framework. Precision measures the number of correctly 
identified entities as a percentage of the number of items 
identified. Recall measures the number of correctly identi-
fied entities as a percentage of the total number of correct 
entities. F-measure is the harmonic mean between precision 
and recall. In this work, we compare the student annotators 
to the expert annotator (Table 6) and the student annotators 
to other student annotators (Table 7). We do not report the 
inter-annotator agreement (eg, Cohen’s Kappa) because 
the concept of a nonentity is not defined, and therefore, the 
number of words contained in the nonentity is not known.
Demonstration of intended use of the 
corpus
We conducted an evaluation of the END corpus on two 
state-of-the-art NER systems. We evaluated the Apache 
OpenNLP Toolkit and Stanford NER. OpenNLP was cre-
ated for processing general English natural language text 
and includes the NameFinder entity recognizer which uses 
a Maximum Entropy supervised learning algorithm to iden-
tify named entities in unstructured text.9 Stanford NER is a 
Java-based Named Entity Recognizer that has previously 
been used to automatically identify general English entities 
(eg, person and company names) and biomedical entities 
(eg, gene and protein names) from natural language text.10 
Stanford NER uses Conditional Random Fields, also known 
as CRFClassifier.11





















Biologic response adverse reaction
Indication
Abbreviations: aUc, area under the curve; cmax, maximum concentration measured 
in blood; FDa, Us Food and Drug admini stration; Tmax, time to reach cmax.





To evaluate the previously developed entity extractors, 
we performed 10-fold cross validation on each of the entity 
extraction models developed for the project for those entities 
that had at least 45 instances in our dataset. Each instance 
contains 10 words to the right and left of the entity. Table 8 
shows the F1 score of the OpenNLP and Stanford NER entity 
extractors, and the number of instances in the current training 
data. The results show that for most entities, the Stanford 
NER system obtains a higher F1 score than the OpenNLP 
entity extractor for all of the entities evaluated. The Stanford 
NER system results show that it is able to identify some 
nano-entities very accurately (eg, molecular weight), but 
others poorly (eg, core composition). As expected, in general, 
entities that had a lower number of instances tended to have 
poorer results than those with more instances, although this 
is not the case for active ingredient.
The results indicate that further investigation is 
required into developing entity extraction methods for 
nanomedicines.
Current state-of-the-art named entity extraction systems, 
such as Stanford NER and OpenNLP, primarily utilize punc-
tuation, lexical information (eg, previous word), morpho-
logic information (eg, prefix), and orthographic information 
(eg, capitalization) as features into a machine learning 
algorithm.12 Although these types of features have been shown 
to perform well for general English entities (eg, People, 
Locations, and Organizations), they have been shown to be 
less useful within the biomedical domain.13 Analysis of the 
features utilized by Stanford NER and OpenNLP shows that 
Stanford NER incorporates more contextual information as 
features than OpenNLP. Our hypothesis is that the incorpora-
tion of this additional contextual information may be respon-
sible for Stanford NER systems higher performance.
Discussion
In this work, we created and evaluated an annotated corpus 
with nanomedicine and pharmacokinetic parameters. 
FDA-approved nanomedicines were chosen due to the 
larger number of publications describing these nanomedi-
cines, compared to those still in the development pipeline. 
We discovered in our chosen document type (ie, drug product 
labels) that a limited number of mentions specific to the 
physicochemical properties of nanomedicines are included. 
Of the 16 minimum characterization parameters extracted 
by other groups, only 5 (core composition, particle diameter, 
molecular weight, surface charge, surface chemistry) were 
Figure 1 annotated ferumoxytol drug product label using gaTe.
Abbreviation: gaTe, general architecture for Text engineering.





the descriptors, that is, physicochemical characterization, 
exposure, and biologic response information, with the asso-
ciated drug.
The 41 nanomedicines included in this corpus were chosen 
based on published literature reviews.4,5 More recent reviews 
identify additional nanomedicines and their drug product 
labels will serve as a test set when evaluating our developed 
entity extractor.14,15 The nanomedicines in the END corpus 
are all nanostructured compounds used for the treatment or 
prevention of disease. We recognize that the definition of 
nanomedicine is still not fully established in the research 
community. Erring on the side of inclusion, the END corpus 
contains conjugate formulations, although PEGylated pro-
teins are not always recognized as nanomedicines.16 Despite 
some limitations, the END corpus can serve as a controlled 
dataset for developing entity extractors for nanomedicine.
Table 3 Entity definitions contained in the annotation guidelines
Class Entity Description
Nanomedicine description company company names, including the drug manufacturer and distributor. When annotating, 
include any of the following abbreviation (eg, co., corp., inc., llc)
FDa approval date The year the nanomedicine was approved for clinical use by the Us FDa
Trade name The trademark name of the nanomedicine. When annotating, do not include the 
registered trademark symbol
Us patents The Us patent number(s) associated with the nanomedicine
Nanoparticle physicochemical 
characterization
active ingredient The chemical composition of the agent that is providing the pharmacologic effect
core composition 
(NPO_1808)
The chemical composition of the nanoparticle
Molecular weight 
(NPO_1171)




The generic name of the nanomedicine (eg, ferumoxytol), the type of nanomedicine 
(eg, antibody–drug conjugate, liposome, lipid complex), or the written description of 
the nanomedicine (eg, paclitaxel formulated as albumin-bound nanoparticles). Part of 
speech variants (eg, liposomal vs liposome) should also be annotated
Particle diameter 
(NPO_1539)




The chemical composition (eg, polyethylene glycol [Peg]) of the surface coating of 
the nanomedicine. When annotating, include the abbreviations
Pharmacokinetics aUc (NPO_1523) area under the curve. The total drug concentration over time
clearance (NPO_1525) The volume of blood from which a drug is irreversibly cleared
cmax (NPO_1527) The maximum concentration measured in the blood
elimination half-life  
(NPO_1522)
The time at which half of the administered dose remains in the body
Plasma half-life 
(NPO_1589)
The time at which half of the maximum concentration of the drug (systemically 
available) remains in the plasma. also referred to as terminal half-life
Tmax (NPO_1528) The time to reach cmax
Volume of distribution 
(NPO_1524)
The theoretical volume of the compartment the drug appears to fill as related to the 
concentration measured in the blood. Vd =	dose/cmax
exposure Dose The administered mass, volume, and/or concentration of the nanomedicine or other 
described drugs. annotations should include units (eg, 5 mg)
route of administration The method in which the nanomedicine is administered to patients. Possible routes 
of administration include: dermal (skin), sc, oral (by mouth), IM, IT, IV, intravitreal
Biologic response adverse reaction Nontherapeutic/off-target/side effects or toxic injury due to taking the nanomedicine
Indication The disease(s) that the nanomedicine is used to detect, treat, or prevent
Abbreviations: cmax, maximum concentration measured in blood; FDa, Us Food and Drug administration; IM, intramuscular; IT, intrathecal; IV, intravenous; Peg, 
polyethylene glycol; sc, subcutaneous; Vd, volume of distribution; NPO, NanoParticle Ontology.
Table 4 summary of corpus text structure
Metric Corpus Liposomes
Number of inserts 41 10
Number of annotations 22,033 4,520
average number of annotations per insert 537 468
average number of sentences 690 542
average number of words 11,363 8,728
Time span, year 1975–2013 1989–2012
contained in the drug product labels.1 Particle diameter 
had the lowest number of entities due to being mentioned 
one to two times in only 6 of the 41 labels. Similarly, only 
15 out of the 41 labels described the surface coating. Future 
work will include full papers from the primary literature to 
develop larger training sets that include data on additional 
characterization parameters as well as relation annotations. 
The inclusion of relation annotations will facilitate linking 





Table 5 statistics on the 21 annotated entities
Class Entity No mentions No unique mentions No labels included
Nanomedicine description company 197 69 41
FDa approval date 34 19 41
Trade name 6,716 41 41
Us patent 31 31 8
Physicochemical characterization active ingredient 2,161 61 41
core composition 89 26 16
Molecular weight 50 40 34
Nanoparticle 854 42 41
Particle diameter 7 6 6
surface coating 62 11 15
Pharmacokinetic parameters aUc 47 46 19
clearance 49 46 24
cmax 45 42 20
elimination half-life 16 15 11
Plasma half-life 56 53 13
Tmax 30 18 14
Volume of distribution 29 27 19
exposure Dose 2,283 542 41
route of administration 1,192 20 41
Biologic response adverse reaction 6,689 1,773 41
Indication 1,396 162 41
Abbreviations: aUc, area under the curve; cmax, maximum concentration measured in blood; FDa, Us food and drug administration; Tmax, time to reach cmax.
Table 6 annotation agreement between student and expert annotator
Class Entity Precision Recall F-measure
Nanomedicine description company 0.96 0.46 0.62
FDa approval date 0.97 1 0.98
Trade name 0.99 1 1
Us patent 1 1 1
Physicochemical characterization active ingredient 0.89 0.79 0.84
Molecular weight 0.89 0.69 0.78
Nanoparticle 0.64 0.42 0.51
Particle diameter 1 0.71 0.83
surface coating 0.48 0.27 0.34
Pharmacokinetic parameters aUc 0.82 0.47 0.60
clearance 0.74 0.65 0.69
cmax 0.91 0.63 0.74
elimination half-life 0.80 0.73 0.76
Plasma half-life 1 0.75 0.86
Tmax 0.91 0.56 0.69
Volume of distribution 0.91 0.87 0.89
exposure Dose 0.86 0.32 0.46
route of administration 0.95 0.49 0.65
Biologic response adverse reaction 0.96 0.06 0.11
Indication 0.98 0.53 0.69
Total 0.95 0.55 0.69
Abbreviations: aUc, area under the curve; cmax, maximum concentration measured in blood; FDa, Us Food and Drug administration; Tmax, time to reach cmax.
Overall agreement between the student annotators and 
the expert annotator was relatively good in light of the wide 
experience gap. Low inter-annotator agreement primarily 
correlated with the complexity of the entity definition and the 
length of description in the drug product insert. For example, a 
common misannotation for dose often included values for the 
dosage form, which does not always equal the administered 
dose. Misannotations for nanoparticle were due to confusion 
with the active ingredient. Contributing factors to the confu-
sion include the label listing the generic name of the nano-
particle as the active ingredient and the student annotators’ 
limited experience identifying components of nanostructures. 





Table 7 annotation agreement between student annotators
Class Entity Precision Recall F-measure
Nanomedicine description FDa approval date 1 0.97 0.99
Trade name 1 1 1
Us patent 1 1 1
Physicochemical characterization active ingredient 0.80 0.89 0.84
Molecular weight 0.93 0.65 0.77
Nanoparticle 0.63 0.68 0.65
Particle diameter 1 0.43 0.60
exposure Dose 0.99 0.56 0.72
route of administration 1 0.67 0.80
Biologic response Indication 0.77 0.94 0.85
Total 0.92 0.90 0.91
Abbreviation: FDa, Us Food and Drug administration. 
Table 8 F-measure of state-of-the-art Ner systems
Class Entity No mentions Open NLP Stanford NER
Nanomedicine description company 197 0.65 0.74
Trade name 6,716 0.72 0.81
Physicochemical characterization active ingredient 2,161 0.59 0.77
core composition 89 0.23 0.27
Molecular weight 50 0.58 0.84
Nanoparticle 854 0.65 0.82
surface coating 62 0.43 0.59
Pharmacokinetic parameters aUc 47 0.26 0.41
clearance 49 0.35 0.31
cmax 45 0.45 0.50
Plasma half-life 56 0.47 0.67
exposure Dose 2,283 0.54 0.68
route of administration 1,192 0.67 0.78
Biologic response adverse reaction 6,989 0.10 0.12
Indication 1,396 0.51 0.64
Abbreviations: aUc, area under the curve; cmax, maximum concentration measured in blood; Ner, named entity recognition; NlP, natural language processing.
This limited experience also resulted in low inter-annotator 
agreement for surface coating. The low precision of surface 
coating is skewed due to misannotations contained in one 
label (Zevalin). The low recall is more representative, since 
the missing annotations for surface coating were consistent 
across the labels. Out of all entities, adverse reaction had the 
lowest recall. This was attributed to adverse reaction having 
the largest number of unique entities and being described in 
several sections of the label. Compared to a study reporting 
inter-annotator agreement between crowdsourced annotations 
and expert annotations, our overall F-measure across all enti-
ties was lower (0.69 vs 0.76).6,7 We believe this is in part due 
to the inclusion of more complex concepts in our entity set 
compared to the biomedical entities, disease and symptom, 
which more people are familiar with from life experience.
The agreement across students was higher for the 10 entities 
that all students completed across all 41 labels. The trends 
observed in the student–student and expert–student agreement 
were similar. For example, the entities that presented the most 
difficulty and consequently resulted in the highest number of 
misannotations between students were active ingredient, dose, 
and nanoparticle. The reasons for the high number of false 
positives are the same to those described above. The student–
student agreement for indication revealed an opposite result, 
low precision and high recall, compared to the expert–student 
agreement, high precision and low recall. This was due to the 
higher number of misannotations when comparing between 
students, compared to missing annotations when comparing 
between the expert and students. Overall, the performance 
of the students for entities that could describe any drug (eg, 
trade name, US patent) was better than for entities specific to 
nanomedicines (ie, nanoparticle, particle diameter).
limitations
Several limitations must be discussed to facilitate the 
interpretation of the results of this study. First, the current 





dataset consists of entities and their context extracted from 
FDA drug labels. It is still unclear if the context describing 
the entities within the labels is similar to that within the 
primary literature. The next step is to utilize this framework 
for a large-scale data creation study that focuses on primary 
literature. During this time, we will compare using the drug 
label dataset as test data for automatically extracting entities 
from labels not in the training set as well as different article 
types (eg, preclinical vs clinical).
Second, the size of the dataset is relatively small. How-
ever, we believe that this dataset and the framework developed 
for its creation can be used to facilitate 1) the development 
of additional larger-scale datasets for nanoparticle entity 
extraction and 2) the evaluation of current state-of-the-art 
NLP methods on secondary bio-focused tasks. For example, 
the pharmacokinetic parameters and biologic response enti-
ties are not solely relevant to nanomedicines (eg, plasma 
half-life, adverse effect). This dataset may be leveraged to 
aid in developing systems to extract this information across 
a wide variety of different types of medications.
Third, many nanomedicines in the pipeline are not repre-
sented by the formulations included in the set based on the cur-
rent FDA-approved nanomedicines. The language describing 
these more sophisticated nanomedicine complexes may differ 
from the FDA-approved nanomedicines based on older tech-
nology. In addition, these new nanomedicines may receive 
FDA approval in the future, and future work will include 
active learning to better cover the complete dataset.17
lessons learned
For this project, we used GATE to manually annotate the 
drug product labels.8 The annotation was conducted using 
the Windows and Mac operating systems. This caused some 
compatibility issues. Future annotations will be conducted 
using a single operating system to avoid these difficulties. 
In addition, manual annotation is a time-consuming and 
sometimes tiresome process. Future work will include 
active learning to focus manual annotation efforts on entities 
that need more instances to improve the entity recognition 
algorithm.
Analysis of current state-of-the-art named entity extrac-
tion systems showed that they are not applicable for each 
of the different nanomedicine parameters extracted by the 
system. Analysis of the parameters also showed that not 
all parameters may need a machine learning component to 
identify them within the text. For example, out of the 1,192 
mentions of Route of Administration, only 20 were unique. 
Given the low performance of identifying this entity by the 
NER systems, incorporating simple rules and a dictionary for 
a hybrid machine learning/rule-based approach may improve 
the overall results of the system.
Conclusion
In this paper, we proposed a framework for creating an 
annotated corpus for nanomedicine entity extraction. We 
validated our framework by annotating a corpus of FDA-
approved nanomedicines from drug product inserts collected 
from the Drugs@FDA Database. We annotated the nanopar-
ticle physicochemical properties, exposure parameters, and 
biologic response information and evaluated the reliability 
of the human ratings. Based on these results, we provided 
guidelines and suggestions for future development of addi-
tional nanomedicine corpora. We provided both the anno-
tated corpus and the statistical software for their analysis 
as open source. Furthermore, we demonstrated the use of 
the proposed framework by evaluating two state-of-the-art 
named entity extraction systems on the corpus. In the future, 
we plan to extend this corpus to include the preclinical and 
clinical trial literature.
Acknowledgments
The authors thank Marley Hodson and Tanin Izadi for serving 
as annotators and Gabriel Jones for assisting with the open-
source NER evaluation. This work was supported by the startup 
funds provided to Dr Lewinski and Dr McInnes by the School 
of Engineering at Virginia Commonwealth University.
This work was presented at the 8th International Nano-
toxicology Congress as a poster presentation with interim 
findings. The poster’s abstract was published in the confer-
ence’s program available at http://www.nanotoxcongress.net/
images/8th-International-Nanotoxicology-Congress.pdf.
Author contributions
NAL and BTM conceived the project idea, led the project, con-
ducted data analysis, and wrote the manuscript. IJ performed 
annotations and assisted with data analysis. All authors con-
tributed toward data analysis, drafting and revising the paper 
and agree to be accountable for all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
1. Lewinski NA, McInnes BT. Using natural language processing tech-
niques to inform research on nanotechnology. Beilstein J Nanotechnol. 
2015;6:1439–1449.
2. Dieb TM, Yoshioka M, Hara S. NaDev: an annotated corpus to support 
information extraction from research papers on nanocrystal devices. 
J Inform Process. 2016;24(3):554–564.
International Journal of Nanomedicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-nanomedicine-journal
The International Journal of Nanomedicine is an international, peer-
reviewed journal focusing on the application of nanotechnology 
in diagnostics, therapeutics, and drug delivery systems throughout 
the biomedical field. This journal is indexed on PubMed Central, 
 MedLine, CAS, SciSearch®, Current Contents®/Clinical Medicine, 
Journal Citation Reports/Science Edition, EMBase, Scopus and the 
Elsevier Bibliographic databases. The manuscript management system 
is completely online and includes a very quick and fair peer-review 
system, which is all easy to use. Visit http://www.dovepress.com/
testimonials.php to read real quotes from published authors.






 3. Drugs@FDA Database. Available from: http://www.accessdata.fda.
gov/scripts/cder/drugsatfda/. Accessed February 8, 2015.
 4. Schütz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M; 
NanoImpactNet Consortium. Therapeutic nanoparticles in clinics and 
under clinical evaluation. Nanomedicine (Lond). 2013;8(3):449–467.
 5. Weissig V, Pettinger TK, Murdock N. Nanopharmaceuticals (part 1): 
products on the market. Int J Nanomedicine. 2014;9:4357–4373.
 6. Good BM, Nanis M, Wu C, Su AI. Microtask crowdsourcing for disease 
mention annotation in PubMed abstracts. Paper presented at: Pacific 
Symposium on Biocomputing. Pacific Symposium on Biocomputing; 
2015:282–293.
 7. Tsueng G, Nanis S, Fouquier J, Good B, Su A. Citizen science for min-
ing the biomedical literature. Citiz Sci Theory Pract. 2016;1(2):14.
 8. Cunningham H. GATE, a General Architecture for Text Engineering. 
Comput Humanit. 2002;36(2):223–254.
 9. Baldridge J, Morton T, Bierner G. The opennlp maximum entropy pack-
age. Tech Rep Source Forge. 2002. Available from: https://sourceforge.
net/projects/maxent/. Accessed October 2, 2017.
 10. Manning CD, Surdeanu M, Bauer J, Finkel JR, Bethard S, McClosky D. 
The stanford corenlp natural language processing toolkit. Paper 
presented at: ACL (System Demonstrations); 2014. Available from: 
https://nlp.stanford.edu/pubs/StanfordCoreNlp2014.pdf. Accessed 
October 2, 2017.
 11. Sutton C, McCallum A. An introduction to conditional random fields. 
Foundations and Trends® in Machine Learning. 2012;4(4):267–373.
 12. Nadeau D, Sekine S. A survey of named entity recognition and clas-
sification. Lingvisticae Investigationes. 2007;30(1):3–26.
 13. Leaman R, Gonzalez G. BANNER: an executable survey of advances 
in biomedical named entity recognition. Paper presented at: Pacific 
Symposium on Biocomputing. 2008:652–663.
 14. Bobo D, Robinson KJ, Islam J, Thurecht KJ, Corrie SR. Nanoparticle-
based medicines: a review of FDA-approved materials and clinical 
trials to date. Pharm Res. 2016;33(10):2373–2387.
 15. D’Mello SR, Cruz CN, Chen ML, Kapoor M, Lee SL, Tyner KM. The 
evolving landscape of drug products containing nanomaterials in the 
United States. Nat Nanotechnol. 2017;12(6):523–529.
 16. Anselmo AC, Mitragotri S. Nanoparticles in the clinic. Bioeng Transl 
Med. 2016;1(1):10–29.
 17. Chen Y, Lasko TA, Mei Q, Denny JC, Xu H. A study of active learning 
methods for named entity recognition in clinical text. J Biomed Inform. 
2015;58:11–18.
